What is InnoCan Pharma Corporation (INNPF)?

InnoCan Pharma Corporation (INNPF) is a stock in the Healthcare sector, Medical - Pharmaceuticals industry. View full analysis on Stocks360.

What is the current price of INNPF?

The current price of INNPF is $1.29. Prices are updated in real time on Stocks360.

What is INNPF's price-to-earnings (PE) ratio?

INNPF's trailing twelve-month PE ratio is -6.54, based on current price and earnings per share data available on Stocks360.

What is INNPF's market capitalization?

INNPF's market capitalization is $5,803,416.00, placing it in the small-cap tier.

InnoCan Pharma Corporation (INNPF)

Stock analysis · OTC · Healthcare · Medical - Pharmaceuticals

$1.29

Market Cap

$5.80M

PE (TTM)

-6.54

EPS (TTM)

N/A

Dividend Yield

0.00%

Beta

-0.22

Day Range

$1.29 – $1.29

52-wk Range

$1.25 – $14.26

Avg Volume

N/A

Volume

0.00

InnoCan Pharma Corporation (INNPF) is a publicly traded company in the Healthcare sector. Latest price: $1.29. Market cap $5.80M. Trailing PE -6.54. Sign in to Stocks360 for full DCF valuation, fundamentals, technicals, and AI-driven analysis.

Get full analysis → Short-Term Analysis →

1-Year Price

2025-11-03 · $12.65 2026-10-26 · $1.29 (-89.80%)

Proprietary Signals

Signal snapshot temporarily unavailable.

About InnoCan Pharma Corporation

InnoCan Pharma Corporation is a pharmaceutical enterprise dedicated to innovating drug delivery systems by integrating cannabidiol (CBD) with diverse pharmaceutical ingredients. Its operations extend across the United States, Poland, France, and other international markets. The company actively pursues research and development into CBD-loaded exosomes for treating conditions like COVID-19, as well as advancing CBD-infused liposomes. InnoCan Pharma also commercializes a range of branded CBD-integrated pharmaceutical and topical treatment products, such as CBD eye serum, face oil, face cream, facial serum, sleeping mask, recovery lotion, and the Relief & Go spray. Established in 2018, the corporation is headquartered in Calgary, Canada.

Valuation

Trailing twelve months. Multiples relative to current market price.
P/E (TTM)	-6.54×
P/S (TTM)	0.26×
P/B	1.27×
PEG	0.06×
P/FCF (TTM)	-3.96×
EV / EBITDA	-1.22×
EV / Sales	0.06×
Earnings Yield	-15.43%
Free Cash Flow Yield	-25.25%

Fundamentals

Trailing twelve months. Source: financial statements via market data.
Enterprise Value	$1.33M
Revenue (TTM)	$23.45M
Net Income (TTM)	-$942.30K
Free Cash Flow (TTM)	-$1.52M
Net Debt	-$4.78M
Working Capital	$7.80M
Gross Margin	90.45%
Operating Margin	-14.60%
Net Margin	-4.02%
Return on Equity	-19.37%
Return on Invested Capital	-35.89%